Nemesis Bioscience Ltd

Overview

Legal name

NEMESIS BIOSCIENCE LTD

Region

London

Registered address

Unknown

Insolvency history

No

Company events

Reference milestones and recent Companies House filing stream events.

1 event

03 Mar

2014

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards

First funded

2015

Funded years

2015, 2017, 2019

Age at first award

1 years

Projects

2019 Small Business Research Initiative Lead participant

DNA Companion Therapeutics for AMR Inactivation in Pathogenic Bacteria

1 Feb 2019 to 31 Jan 2020

Awarded

£414,320

Total cost £414,320

Nemesis Bioscience believes that any attempt to kill bacteria directly will only result in selection for resistance and that the answer to the problem of AMR is to switch off resistance via an agent which will not kill bacteria directly – leaving the killing to be done by subsequent treatment with antibiotics. The company has proved it can do so effective...

2017 Feasibility Studies Lead participant

Inactivation of Antibiotic Resistance in Clinical Isolates of Pathogenic Enterobacteriaceae

1 Dec 2017 to 31 Aug 2018

Awarded

£103,686

Total cost £148,123

Nemesis Bioscience has invented, developed and protected a family of novel biological therapeutic agents that inactivate resistance to antibiotics, so allowing well-established and safe antibiotics to be effective again. Resurrecting antibiotic susceptibility eliminates the threat of ‘super bugs’ and ensures current and newly developed antibiotics retain ...

2015 GRD Proof of Market Lead participant

Transmids: A Novel Vehicle for Delivery of Polynucleotide Constructs into Bacteria

1 Aug 2015 to 31 Jan 2016

Awarded

£24,000

Total cost £40,583

Nemesis Bioscience Ltd has invented, developed and protected a family of novel biological therapeutic agents that inactivate resistance to antibiotics, so allowing well-established safe generic antibiotics to be effective again. The company has proven in the laboratory that its “Nemesis Symbiotics” convert antimicrobial resistant (AMR) bacteria to antibio...

Product types

Feasibility Studies GRD Proof of Market Small Business Research Initiative